On October 11, our company's novel DAP CAR-T cells therapy achieved initial success in the treatment of a patient with relapsed and refractory advanced ovarian cancer in the Jiangsu Provincial People's Hospital. The patient's pleural and ascites were completely controlled , and the levels of tumor markers in the peripheral blood decreased significantly. The clinical response of MSLN-DAP12 CAR-T cell therapy heralds a major breakthrough in the application of CAR-T cell therapy for solid tumors!
Victory in the first battle
●Nanjing KATI has cooperated with Jiangsu Provincial People's Hospital on the clinical trial of novel DAP12 CAR-T cell therapy for the advanced solid tumors (Ovarian Cancer, Mesothelioma and Pancreatic Cancer). During the entire clinical trial process, the patient's treatment costs are all free!
● During the study, our clinical team carefully screened the patient population. Ms. Liu, a patient with ovarian cancer, has received up to 53 times of chemotherapy in the past 5 years. All treatments cannot effectively control the disease. After fully evaluating the patient's condition, Ms. Liu was admitted to the hospital for severe pleural and ascites. Then, Ms. Liu was infused with MSLN-DAP12 CAR-T cells to control the disease progress. During this period, the patient experienced "cytokine storms", but passed smoothly. After 1 month, Ms. Liu's pleural and ascites almost disappeared, and the tumor markers were significantly reduced.
Ms. Liu is a professor of a university in Nanjing，and has suffered from the ovarian cancer for 5 years. For this reason, she has to go to the hospital for chemotherapy almost every month in recent years. The disease stabilized and then recurred repeatedly. The cough caused by long-term drug treatment has also been seriously affecting her quality of life.
Fortunately, the rapid progress of Ms. Liu's disease coincided with Nanjing KATI Medical Technology Co., Ltd., and the team of Professor Shu Yongqian (Director of the Department of Oncology in Jiangsu Provincial People's Hospital), launched a clinical trial of CAR-T cells therapy of advanced solid tumors. Under the premise of fully satisfying the entry conditions and fully informed by Ms. Liu, our company closely cooperated with Professor Shu's team to implement CAR-T cell therapy. The infused CAR-T cells proliferated very ideally (completely equivalent to hematological CAR-T), and triggered a certain cytokine storm. Deputy Chief Physician Dr.Xu and the nursing team properly handled the corresponding reactions, and the patient went through the period smoothly. One month after the infusion, the patient's clinical symptoms improved significantly. For example, the pleural and ascites fluids were completely controlled, the tumor markers decreased, and the CAR-T cells continued to stabilize at a high level. To date, Ms. Liu has been discharged from the hospital, and the treatment has entered the long-term follow-up stage.
This is the first domestic and even the world's first clinical systematic study using a novel CAR technology (KIRS2/DAP12 architecture) to therapy advanced ovarian cancer.
Make persistent efforts
CAR-T refers to chimeric antigen receptor T-cell immunotherapy, which uses the patient's own immune cells that was transformed and cultured in vitro to get enough CAR-T cells that can target and eradicate cancer cells. Then, prepared CAR-T cells were infused into the patient to achieve the purpose of eradicating cancer cells. Ms. Liu has undergone peripheral blood mononuclear cell apheresis and T lymphocyte sorting. Isolated T cells were transformed with CAR, cultured and proliferated in vitro, and then infused into Ms. Liu after pre-treatment.
● Professor Shu Yongqian said that CAR-T cell immunotherapy is still "young" compared with other tumor treatment methods. The world's first case that received CAR-T cells therapy was in 2012, named Emily Whitehead, a pediatric patient with refractory and relapsed acute lymphoblastic leukemia in the United States and was successfully cured. At present, CAR-T cells therapy for relapsed and refractory solid tumors has become a hot spot in clinical research. As a new type of cellular immunotherapy, it is considered to be one of the most promising tumor treatments.
Professor Shu also said that CAR-T technology has subverted the previous forms of molecular targeting and chemical drugs. The unit of its anti-cancer effect is cells, which is a "living drug". However, CAR-T cells is not a panacea and not the "terminator" of tumors. CAR-T cell therapy can work in the field of hematological tumors such as lymphoma. All previous CAR-T treatments tried in the field of solid tumors have failed. But even so, CAR-T cell therapy is still a very promising treatment method, and technological advances may bring more beneficiaries in the near future.
Dr. Wang Enxiu, chairman of Nanjing KATI Medical Technology Co., Ltd., said in an interview: "Generally, CAR-T technology uses artificially modified T lymphocytes to be infused back into the human body to fight tumor cells. The "engines" of the "Cell Warrior" produced by the previous technology have all been "turned off" after entering the solid tumor microenvironment. While, the new CAR-T therapy applied this time equipped "cell warriors" with a brand new "engine". In addition to ovarian cancer, with different "targets" in the future, this emerging technology is also expected to work on other solid tumors.
patient recruitment
The project "Clinical trial of Chimeric Antigen Receptor Gene-Modified Autologous T Cells (CAR-T) for Advanced Solid Malignant Tumors", jointly developed by Nanjing KATI Medical Technology Co., Ltd. and Jiangsu Provincial People's Hospital, is recruiting subjects.
About Nanjing KATI
Nanjing KATI Medical Technology Co., Ltd. is a new Cell therapy research and development company. The company is committed to the research and development of novel CAR-T cells for the treatment of malignant solid tumors. Relying on the company's advanced immune receptor library technology platform, Nanjing KATI has successfully developed a number of R&D pipelines, including DAP-CAR-T for resisting the tumor microenvironment, VIVO CAR manufactured rapidly with low cost, TCR like CAR-T that redirects TCR signal, and dual-targeting CAR-T. 38 domestic and foreign patents have been declared, and 3 patents have been authorized.
Nanjing KATI is an innovative cell therapy company founded by Dr. Wang Enxiu, a core member of the Carl June team, a pioneer in CAR-T immunotherapy. The University of Pennsylvania is the cradle of growth in CAR-T cell development. Nanjing KATI adheres to its pioneering and pragmatic style, and is committed to the development and application of independent innovative cell therapies.
Since its establishment in 2017, the company has formed four new product matrices and dozens of product pipelines around the "recognition, activation, carrier, and process" of solid tumor cell therapy, and the most mature product pipeline has fully entered the rapid process of industrialization.
Innovation is the driving force of Nanjing KATI, and transformation is the way of Nanjing KATI's forward. Innovation and continuous innovation make new technologies and new products always at the forefront of the field; transformation and efficient transformation make new technologies quickly become new drugs that serve patients clinically!
